Ruxolitinib Cream Hit 79% Response Rate in HS Phase 2 Trial
A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now underway.
Topic: Hidradenitis Suppurativa
Hidradenitis Suppurativa Affects 2% of Americans. Most Have Never Heard of It.
Hidradenitis suppurativa affects up to 2% of Americans and is often mistaken for acne. Dermatologists explain symptoms, causes, and treatments including the 2023 FDA-approved biol…
